Schedule Update - effective 1 June 2008 (text extract)

This is the text extract for Schedule Update - effective 1 June 2008, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 June 2008 Cumulative for May and June 2008

Contents

Summary of PHARMAC decisions effective 1 June 2008 ................................ 3 Rizatriptan – New Listing of Migraine Treatment .......................................... 5 New Access Criteria for Losartan and Losartan with Hyrdrochlorothiazide .... 5 New Brand of Salbutamol Inhaler subsidised ................................................ 5 Changes to Close Control Rules ..................................................................... 6 Delisting of Valaciclovir now 1 July 2008 ...................................................... 6 Tender News .................................................................................................. 7 Looking Forward ........................................................................................... 7 Sole Subsidised Supply products cumulative to June 2008 ........................... 8 New Listings ................................................................................................ 18 Changes to Restrictions ............................................................................... 20 Changes to Subsidy and Manufacturer’s Price............................................. 25 Changes to General Rules............................................................................ 27 Changes to PSO........................................................................................... 28 Changes to Sole Subsidised Supply ............................................................. 28 Delisted Items ............................................................................................. 29 Items to be Delisted .................................................................................... 31 Section H changes ....................................................................................... 33 Index ........................................................................................................... 35

Summary of PharmaC decisions

effeCtive 1 juNe 2008 New listing (page 18) • Hydroxocobalamin (ABM) inj 1 mg per ml, 1 ml • Heparinised saline (Hospira) inj 100 iu per ml, 2 ml • Losartan (Cozaar) tab 25 mg – Special Authority for subsidy • Condoms (Gold Knight) 49mm (12 and 144 pack) 53mm chocolate (144 pack), 53 mm strawberry (144 pack), 53 mm extra strength (12 and 144 pack), 55 mm (12 and 144 pack) – Available on a PSO • Levonorgestrel (Postinor-1) tab 1.5 mg – Maximum of 1 tab per prescriptin, available on a PSO • Oestradiol valerate (Progynova) tab 1 mg, 56 tab pack size • Lamotrigine (Logem) tab dispersible 25 mg, 50 mg, 100 mg • Rizatriptan benzoate (Maxalt Melt) wafer 10 mg • Salbutamol (Respigen) aerosol inhaler 100 μg per dose – Available on a PSO • Oral supplement (Fortisip) 1 kcal/ml powder vanilla 54 g sachet, 10 pack – Special Authority for subsidy • Diabetic enteral feed (Glucerna Select RTH) 1kcal/ml Liquid – Special Authority for subsidy • Oral feed (Glucerna Select) 1kcal/ml Liquid – Special Authority for subsidy Changes to restriction (pages 20-23) • Losartan (Cozaar) – amended Special Authority criteria • Losartan with hydrochlorothiazide (Hyzaar) – amended Special Authority criteria • Gabapentin, topiramate and vigabatrin – amended Special Authority criteria • Carbohydrate supplement – amended Special Authority criteria Decreased subsidy (page 25) • Losartan (Cozaar) tab 12.5 mg and 50 mg • Losartan with hydrochlorothiazide tab 50 mg with hydrochlorothiazide 12.5 mg (Hyzaar) • Cefuroxime sodium (Zinacef) inj 750 mg and 1.5 g • Aspirin (Ethics Aspirin) tab dispersible 300 mg, 1000 pack size • Morphine sulphate (Mayne) inj 10 mg per ml and inj 30mg per ml • Salbutamol (Salamol, Ventolin) aerosol inhaler 100 μg per dose CFC-free

Summary of PharmaC decisions – effective 1 june 2008 (continued) increased subsidy (pages 25-26) • Paraffin (IPW) white soft • Acetic acid with 1, 2-propanediol diacetate and benzethonium (Vosol) ear drops • Carbohydrate and fat supplement (Duocal super soluble powder) • Fat supplement (Liquigen and MCT Oil Nutricia) oil • Fat modified feed (Monogen) powder • Enteral / oral feed (Generaid Plus) 1kcal/ml powder • Enteral / oral feed (Kindergen) 1kcal/ml liquid • Oral elemental feed (Elemental 028 extra) liquid - grapefruit, pineapple and orange, summer fruit • Multivitamins (Paedatric Seravite) powder • Low calcium infant formula (Locasol) powder

5 Pharmaceutical Schedule - Update News

Rizatriptan – New Listing of Migraine Treatment

People who suffer from migraine headaches will have another treatment available fully subsidised from 1 June 2008. Rizatriptan 10 mg wafer (Maxalt Melt) is designed to be placed on the tongue where it will dissolve and be swallowed with the saliva. It will be particularly useful for patients who feel so ill they can’t swallow tablets. Rizatriptan will also provide a useful alternative for those people who don’t respond to or can’t tolerate sumatriptan.

New Access Criteria for Losartan and Losartan with Hydrochlorothiazide

The Special Authority criteria for losartan (Cozaar) and losartan with hydrochlorothiazide (Hyzaar) are being amended to provide wider access. As the access criteria are the same patients can switch between the products where appropriate using the same Special Authority approval. Current Special Authority approvals for losartan with hydrochlorothiazide will be extended so that renewals will not be required. The price and subsidy of Cozaar and Hyzaar will be reduced from 1 June 2008. The Special Authority criteria for candesartan will remain unchanged. See page 20 of this Update for full details.

New Brand of Salbutamol Inhaler subsidised

The Respigen brand of salbutamol inhaler 100 μg per dose will be fully subsidised from 1 June 2008. The subsidy for Salamol and Ventolin will be reduced to the same level as Respigen. The supplier of Salamol has reduced the price of Salamol so that it will remain fully subsidised. There will be a higher part charge on Ventolin inhalers. The three funded brands of salbutamol inhaler are therapeutically equivalent but differ slightly in appearance, taste and spray pressure. People can perceive differences in effects of equivalent brands of the same medicine and may need some reassurance that the new brand will have the same effect on their asthma as the old one. We have provided some resources to help explain the new listing and provide answers to some frequently asked questions. If you need any more of these resources please contact PHARMAC by calling 0800 11 22 37 or emailing resources@pharmac.govt.nz

Pharmaceutical Schedule - Update News

Changes to Close Control Rules

The Close Control rules will be changing from 1 June 2008. These changes are: • Small quantities of medicines can be dispensed to patients who start a new treatment or have their dose changed. • People in rest homes or residential care facilities can have their prescriptions dispensed Close Control in monthly lots. • Pharmacists can endorse prescriptions Close Control when PHARMAC has notified pharmacists they can do so. The changes are intended to help medicines management overall, and help reduce unused medicines in the community. We expect the first two changes to have the greatest impact on pharmacists. The third simply formalises a process that is used in situations like when we have to manage limited stocks of medicines. We have produced some resources to help explain what these changes mean. If you require further copies of these resources please contact PHAMAC by calling 0800 11 22 37 or emailing resources@pharmac.govt.nz.

Delisting of Valaciclovir now 1 July 2008

At the end of April, valaciclovir (Valtrex) tab 500 mg was listed in the Pharmaceutical Schedule from 1 May 2008 to 1 June 2008 to cover a potential short term out-of-stock of aciclovir tab 800 mg (Lovir). As there has been a short delay in the dispatch of Lovir 800 mg from the manufacturer, we have extended the listing of Valtrex 500 mg tablets to 30 June 2008. It is now expected that Lovir 800 mg tablets will be available for dispatch to wholesalers in New Zealand during the week of 19 May 2008.

tender News

Sole Subsidised Supply changes – effective 1 July 2008

There are no pharmaceuticals becoming Sole Subsidised Supply effective 1 July 2008

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule. Possible decisions for implementation 1 july 2008 • Amitriptyline tab 10m g (Amirol) – new listing • Betamethasone valerate cream 0.1% (Beta Cream) and ointment 0.1% (Beta Ointment) - price and subsidy increase • Combivent (salbutamol 100 mcg with ipratropium bromide 20 mcg aerosol inhaler) - price and subsidy increase • Condoms 52 mm (Marquis Supalite), 52 mm extra strength (Marquis Protecta), 54 mm, shaped (Lifestyle Flared), 56 mm, shaped (Durex Confidence) - subsidy decrease • Co-trimoxazole oral liquid trimethoprim 40mg and sulphamethoxazole 20mg per 5 ml (Deprim) – new listing

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Acetazolamide Acipimox Acitretin Allopurinol Alprazolam

Presentation

Tab 250 mg Cap 250 mg Cap 10 mg & 25 mg Tab 100 mg & 300 mg Tab 250 µg Tab 500 µg Tab 1 mg Tab 10 mg, 25 mg & 50 mg Tab 5 mg & 10 mg Inj 10 mg per ml, 1 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Inj 250 mg, 500 mg & 1 g Device Cream Tab 100 mg Tab 100 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Inj 1200 µg, 1 ml Eye drops 1% Tab 500 mg Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg Scalp app 0.1% Crm 0.1% Oint 0.1% Tab 200 mg Tab 5 mg Eye drops 0.2% Tab 2.5 mg & 10 mg Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Lotion BP Crm, aqueous, BP Cap 0.25 µg & 0.5 µg Tab dispersible 2.5 g Tab 1.25 g Tab 1.5 g

Brand Name Expiry Date*

Diamox Olbetam Neotigason Progout Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam Amitrip Calvasc Mayne Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin Ibiamox Ortho Multichem Apo-Ascorbic Acid Ethics Aspirin EC Loten AstraZeneca AstraZeneca Atropt Arrow-Azithromycin Alanase Alanase Beta Scalp Beta Cream Beta Ointment Fibalip Lax-Tab AFT Alpha-Bromocriptine Marcain Isobaric Marcain Heavy ABM ABM Calcitriol-AFT Calci-Tab Effervescent Calci-Tab 500 Calci-Tab 600 2008 2008 2008 2008 2010

Amitriptyline Amlodipine Apomorphine hydrochloride Amoxycillin

2008 2008 2009 2010 2009 2008 2008 2008 2009 2010 2009 2009 2008 2009 2009 2009 2008 2008 2010 2008 2008 2010 2009 2009 2008

Applicator Aqueous cream Ascorbic acid Aspirin Atenolol Atropine sulphate

Azithromycin Beclomethasone dipropionate Betamethasone valerate

Bezafibrate Bisacodyl Brimonidine tartrate Bromocriptine mesylate Bupivicaine hydrochloride Calamine Calcitriol Calcium carbonate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 8

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Calcium folinate Captopril Cefaclor monohydrate Cefazolin sodium Ceftriaxone sodium Cetirizine hydrochloride Cetomacrogol Chloramphenicol Chlorhexidine gluconate

Presentation

Inj 50 mg Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml Inj 500 mg & 1 g Inj 500 mg & 1 g Oral liq 1 mg per ml Tab 10 mg Crm BP Eye drops 0.5% Eye oint 1% Handrub 1% with ethanol 70% Mouthwash 0.2% Soln 4% Tab 25 mg Tab 250 mg, 500 mg & 750 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml Crm 0.05% Scalp app 0.05% Oint 0.05% Tab 500 µg & 2 mg TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day Tab 25 µg Tab 150 µg Inj 150 µg per ml, 1 ml Vaginal crm 1% with applicator(s) Crm 1% Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg Powder for soln for oral use

Brand Name Expiry Date*

Calcium Folinate Ebewe Apo-Captopril Ranbaxy Cefaclor Ranbaxy Cefaclor m-Cefazolin AFT Allerid C Razene PSM Chlorsig Chlorsig Orion Orion Orion Hygroton Cipflox Klamycin Klacid Dalacin C Dermol Dermol Dermol Paxam Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Dixarit Catapres Catapres Clomazol Clomazol PSM Colgout Colestid Colistin-Link Enerlyte 2008 2010 2010 2008 2008 2008 2010 2009 2009 2008 2009 2008 2010 2008 2009 2008 2008 2008

Chlorthalidone Ciprofloxacin Clarithromycin Clindamycin Clobetasol propionate

Clonazepam Clonidine

Clonidine hydrochloride

2008

Clotrimazole Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate Compound electrolytes

2010 2008 2010 2010 2010 2010 2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 9

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Co-trimoxazole

Presentation

Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml Tab trimethoprim 80 mg and sulphamethoxazole 400 mg Tab 50 mg Inj 50 mg per ml, 1 ml Tab 50 mg Tab 50 mg Cap 25 mg & 50 mg Inj 500 mg Nasal spray 10 µg per dose Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Tab 5 mg Oral soln with electrolytes

Brand Name Expiry Date*

Trisul 2008

Cyclizine hydrochloride Cyclizine lactate Cyclophosphamide Cyproterone acetate Dantrolene sodium Desferrioxamine mesylate Desmopressin Dexamethasone sodium phosphate Dexamphetamine sulphate Dextrose with electrolytes

Nausicalm Valoid (AFT) Cycloblastin Siterone Dantrium Mayne Desmopressin-PH&T Mayne PSM Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Ortho All-flex & Ortho Coil Apo-Diclo Apo-Diclo SR Videx EC DHC Continus Diastop Pytazen SR Coloxyl Apo-Doxazosin AFT m-Enalapril Mayne Cafergot E-Mycin E-Mycin Myambutol New Zealand Medical and Scientific

2009 2008 2010 2009 2009 2010 2008 2009 2010 2010

Diaphragm Dicloflenac sodium Didanosine (DDI) Dihydrocodeine tartrate Diphenoxylate hydrochloride with atropine sulphate Dipyridamole Docusate sodium Doxazosin mesylate Emulsifying ointment BP Enalapril Ergometrine maleate Ergotamine tartrate with caffeine Erythromycin ethyl succinate Ethambutol hydrochloride Ethinyloestradiol

Range of sizes Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Cap 125 mg, 200 mg, 250 mg & 400 mg Tab long-acting 60 mg Tab 2.5 mg with atropine sulphate 25 µg Tab long-acting 150 mg Tab 50 mg & 120 mg Tab 2 mg & 4 mg Ointment Tab 5 mg, 10 mg & 20 mg Inj 500 µg per ml, 1 ml Tab 1 mg with caffeine 100 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Tab 400 mg Tab 10 µg

2008 2009 2009 2008 2008 2008 2008 2010 2008 2009 2009 2009 2008 2008 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 10

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Ethinyloestradiol with norethisterone

Presentation

Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab Tab 35 µg with norethisterone 500 µg and 7 inert tab Cap 50 mg & 100 mg Oral liq 150 mg per 5 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 50 mg, 150 mg & 200 mg Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Eye drops 0.1% Cap 20 mg Tab disp 20 mg, scored Inj 12.5 mg per 0.5 ml, 0.5 ml Inj 25 mg per ml, 1 ml Inj 100 mg per ml, 1 ml Tab 0.8 mg & 5 mg Crm 2% & Oint 2% Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml Inj 50 mg per ml, 1 ml Inj 100 mg per ml, 1 ml Inj 10 iu per ml, 5 ml Tab 5 mg & 20 mg Powder 25 g Rectal foam 10%, CFC-Free Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil

Brand Name Expiry Date*

Brevinor 21 Brevinor 1/21 Brevinor 1/28 Norimin Vepesid Ferodan Staphlex AFT AFT Pacific Ultraproct Ultraproct 2008 2009 2010 2009 2010

Etoposide Ferrous sulphate Flucloxacillin sodium

Fluconazole Fluocortolone caproate with fluocortolone pivalate and cinchocaine

2008 2010

Fluorometholone Fluoxetine hydrochloride Fluphenazine decanoate

Flucon Fluox Fluox Modecate Modecate Modecate Apo-Folic Acid Foban Pfizer Apo-Gliclazide Minidiab Serenace Serenace Serenace Haldol Haldol Concentrate AstraZeneca Douglas m-Hydrocortisone Colifoam Locoid DP Lotn HC

2009 2010 2008

Folic Acid Fusidic acid Gentamicin sulphate Gliclazide Glipizide Haloperidol

2009 2010 2009 2008 2008 2010 2009 2008 2009 2009 2008 2009 2010 2008

Haloperidol decanoate Heparinised saline Hydrocortisone Hydrocortisone acetate Hydrcortisone butyrate Hydrocortisone with wool fat and mineral oil

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 11

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Hyoscine N-butylbromide Hypromellose Ibuprofen Imipramine hydrochloride Indapamide Indomethacin Ipratropium bromide

Presentation

Tab 10 mg Inj 20 mg Eye drops 0.3% Eye drops 0.5% Oral liq 100 mg per 5 ml, 200 ml Tab 200 mg Tab 10 mg & 25 mg Tab 2.5 mg Cap 25 mg & 50 mg Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Aerosol inhaler, 20 µg per dose CFC-free Tab long-acting 60 mg Cap 10 mg Cap 20 mg Cap 100 mg Shampoo 2% Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Gastrosoothe Buscopan Poly-Tears Methopt Fenpaed I-Profen Tofranil Napamide Rheumacin Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Atrovent Duride Isotane 10 Isotane 20 Sporanox Ketopine Duphalac Betagan Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250 Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril Nodia Loraclear Hayfever Relief Lorapaed Ativan Mayne Derbac M 2009 2010 2010 2010 2008 2008 2010 2008 2009 2009 2008 2010 2008 2009 2009 2010 2008 2010 2010 2009

Isosorbide mononitrate Isotretinoin Itraconazole Ketoconazole Lactulose Levobunolol Levodopa with benserazide

Lignocaine hydrochloride

Lignocaine with prilocaine

2010

Lisinopril Loperamide hydrochloride Loratadine

Lorazepam Magnesium sulphate Malathion

Tab 1 mg & 2.5 mg Inj 49.3% Liq 0.5%

2009 2009 2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 12

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Maldison Maprotiline hydrochloride Medroxyprogesterone acetate Mesalazine Metformin hydrochloride Methadone hydrochloride Methotrexate

Presentation

Shampoo 1% Tab 25 mg & 75 mg Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Tab 500 mg & 850 mg Tab 5 mg Powder 1 g Tab 2.5 mg & 10 mg Inj 100 mg per ml, 5 ml Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Tab 125 mg, 250 mg & 500 mg Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg Tab 4 mg & 100 mg Crm 0.1% and oint 0.1% Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab long-acting 200 mg Cap 250 mg Cap 50 mg & 200 mg Crm 2% Tab 2.5 mg & 5 mg Tab 200 µg Tab 150 mg & 300 mg Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml

Brand Name Expiry Date*

A-Lices Ludiomil Provera Pentasa Arrow-Metformin Methatabs AFT Methoblastin Methotrexate Ebewe Methotrexate Ebewe Methotrexate Ebewe Prodopa Rubifen SR Rubifen Rubifen Medrol Advantan Depo-Medrol Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Slow-Lopressor Metopirone Mexitil Multichem Gutron Cytotec Apo-Moclobemide RA-Morph RA-Morph RA-Morph RA-Morph 2010 2009 2010 2009 2009 2010 2009 2009 2008

Methyldopa Methylphenidate hydrochloride

2008 2009

Methylprednisolone Methylprednisolone aceponate Methylprednisolone acetate Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol tartrate Metyrapone Mexiletine hydrochloride Miconazole nitrate Midodrine Misoprostol Moclobemide Morphine hydrochloride

2009 2009 2008 2008 2009

2008 2009 2009 2008 2008 2009 2009 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 13

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Morphine sulphate

Presentation

Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg Inj 80 mg per ml, 1.5 ml & 5 ml Tab 40 mg & 80 mg Tab 50 mg Eye drops 0.1% Tab 250 mg Tab 500 mg Tab long-acting 750 mg Tab long-acting 1000 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 50 mg & 500 mg Tab long-acting 20 mg Jelly 2% Tab 350 µg Tab 5 mg Tab 400 mg Tab 10 mg & 25 mg Cap 500,000 u Tab 500,000 u Vaginal crm 100,000 u per 5 g with applicators Oral liq 100,000 u per ml Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml and 2 ml Oral liq 5 mg per 5 ml Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml

Brand Name Expiry Date*

Mayne Mayne m-Eslon Sevredol Mayne Apo-Nadolol ReVia Naphcon Forte Noflam 250 Noflam 500 Naprosyn SR 750 Naprosyn SR 1000 Sonaflam AstraZeneca Viramune Suspension Apo-Nicotinic Acid Nyefax Retard Gynol II Noriday 28 Primolut-N Arrow-Norfloxacin Norpress Nilstat Nilstat Nilstat Nilstat Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol 2009 2010 2010 2008 2009 2008 2010 2010 2009 2009 2009 2008 2009 2008 2008 2008 2010 2009 2008 2010 2010 2010 2009 2009

Morphine tartrate Nadolol Naltrexone hydrochloride Naphazoline hydrochloride Naproxen

Naproxen sodium Neostigmine Nevirapine Nicotinic acid Nifedipine Nonoxynol-9 Norethisterone Norfloxacin Nortriptyline Nystatin

Ondansetron Oxybutynin Oxycodone hydrochloride Oxytocin

Pamidronate disodium

2008

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 14

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Pantoprazole

Presentation

Tab 20 mg Tab 40 mg

Brand Name Expiry Date*

Dr Reddy’s Pantoprazole Dr Reddy’s Pantoprazole Panadol Panadol Junior Parapaed Six Plus Parapaed Codalgin Laci-Lube Loxamine Permax Pexsig AFT AFT Cilicaine VK Cilicaine VK Prefrin Pilopt Coloxyl Span-K AstraZeneca AstraZeneca Apo-Prednisone MDS Quick Card Cilicaine Allersoothe Apo-Pyridoxine Accupril Accuretic 10 Accuretic 20 Q 200 Q 300 Peptisoothe Arrow Ranitidine Mycobutin Arrow-Roxithromycin 2009 2010 2008 2010 2009 2010

Paracetamol

Tab 500 mg Suppos 125 mg & 250 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab 500 mg with 8 mg codeine Eye oint with soft white paraffin Tab 20 mg Tab 0.25 mg & 1 mg Tab 100 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg Cap potassium salt 500 mg Eye drops 0.12% Eye drops 0.5%, 1%, 2%, 4% & 6% Oral drops 10% Tab long-acting 600 mg Inj 75 mg per ml, 10 ml Inj 150 mg per ml, 10 ml Tab 1 mg, 2.5 mg, 5 mg & 20 mg Cassette Inj 1.5 mega u Tab 10 mg & 25 mg Tab 50 mg Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Tab 200 mg Tab 300 mg Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg Cap 150 mg Tab 150 mg & 300 mg

2008

Paracetamol with codeine Paraffin liquid with soft white paraffin Paroxetine hydrochloride Pergolide Perhexiline maleate Phenoxymethylpenicillin (Penicillin V)

2008 2010 2010 2008 2009 2010

Phenylephrine hydrochloride Pilocarpine Poloxamer Potassium chloride

2010 2008 2008 2009 2008 2008 2009 2008 2008 2009 2008 2008

Prednisone Pregnancy tests - HCG urine Procaine penicillin Promethazine hydrochloride Pyridoxine hydrochloride Quinapril Quinapril with hydrochlorothiazide

Quinine sulphate Ranitidine hydrochloride Rifabutin Roxithromycin

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 15

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Salbutamol

Presentation

Nebuliser soln 1 mg per ml, 2.5 ml Nebuliser soln 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg Tab 5 mg Inj 0.9%, 5 ml & 10 ml Grans eff 4 g sachets Nasal spray 4% Tab 500 mg Tab EC 500 mg Liq Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium Tab 10 mg Tab 250 mg Tab 10 mg Tab 50 mg Crm & Oint 0.02% Dental Paste USP 0.1% Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g Tab 125 µg Tab 250 µg Tab 300 mg Cap 25 mg & 50 mg Crm 10% Cap 300 mg Inj 50 mg per ml, 10 ml Tab long-acting 120 mg Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Tab (BPC cap strength) Tab, strong, BPC Purified for injection 20 ml

Brand Name Expiry Date*

Asthalin Asthalin Salapin Duolin Apo-Selegiline AstraZeneca Ural Rex Salazopyrin Salazopyrin EN Midwest Pinetarsol Normison Apo-Terbinafine Apo-Timol Apo-Thiamine Aristocort Oracort Kenacomb Kenacomb 2009 2010 2009 2009 2009 2010 2009 2009 2010 2008 2008 2008 2009 2009 2008 2009 2008

Salbutamol with ipratropium bromide Selegiline hydrochloride Sodium chloride Sodium citro-tartrate Sodium cromoglycate Sulphasalazine Syrup (pharmaceutical grade) Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terbinafine Timolol maleate Thiamine hydrochloride Triamcinolone acetonide Triamcinolone acetonide with gramicidin, neomycin and nystatin

Triazolam Trimethoprim Trimipramine maleate Urea Ursodeoxycholic acid Vancomycin hydrochloride Verapamil hydrochloride Vincristine sulphate Vitamins Vitamin B complex Water

Hypam Hypam TMP Tripress Nutraplus Actigall Pacific Verpamil SR Mayne Mayne Healtheries Apo-B-Complex Multichem

2008 2008 2008 2008 2008 2008 2008 2009 2009 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 16

Sole Subsidised Supply Products – cumulative to June 2008

Generic Name

Zinc and castor oil Zinc sulphate Zopiclone June changes are in bold type

Presentation

Oint BP Cap 220 mg Tab 7.5 mg

Brand Name Expiry Date*

Multichem Zincaps Apo-Zopiclone 2008 2008 2008

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 17

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 June 2008

35 46 54 70 HYDROXOCOBALAMIN ❋ Inj 1 mg per ml, 1 ml ................................................................. 9.21 HEPARINISED SALINE ❋ Inj 100 iu per ml, 2 ml ............................................................... 8.30 LOSARTAN – Special Authority see SA0911 – Retail Pharmacy ❋ Tab 25 mg ............................................................................. 20.31 CONDOMS ❋ 49mm - Up to 144 dev available on a PSO ................................ 1.11 ❋ 49mm - Up to 144 dev available on a PSO ............................... 13.36 ❋ 53mm (chocolate) - Up to 144 dev available on a PSO............. 13.36 ❋ 53mm (strawberry) - Up to 144 dev available on a PSO ........... 13.36 ❋ 55mm - Up to 144 dev available on a PSO ................................. 1.11 ❋ 55mm - Up to 144 dev available on a PSO .............................. 13.36 ❋ 53mm extra strength - Up to 144 dev available on a PSO ........... 1.11 ❋ 53mm extra strength - Up to 144 dev available on a PSO ......... 13.36 LEVONORGESTREL ❋ Tab 1.5 mg ............................................................................ 12.50 a) Maximum of 1 tab per prescription b) Up to 5 tab available on a PSO OESTRADIOL VALERATE ❋ Tab 1 mg .................................................................................. 8.24 LAMOTRIGINE s Tab dispersible 25 mg ............................................................. 19.38 s Tab dispersible 50 mg ............................................................. 32.97 s Tab dispersible 100 mg ........................................................... 56.91 RIZATRIPTAN BENZOATE Wafer 10 mg ........................................................................... 25.32 SALBUTAMOL Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO ...................................... 3.80 3 ✔ ABM Hydroxocobalamin ✔ Hospira S29 ✔ Cozaar ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight ✔ Gold Knight

10 28 12 144 144 144 12 144 12 144 1

✔ Postinor-1

79 110 112 147

56 56 56 56 3

✔ Progynova

✔ Logem ✔ Logem ✔ Logem ✔ Maxalt Melt

200 dose OP ✔ Respigen

167 168 168

ORAL SUPPLEMENT 1KCAL/ML – Special Authority see SA0583 – Hosptial pharmacy [HP3] Powder (vanilla) sachet 54 g ..................................................... 6.91 10 ✔ Fortisip Powder DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid ........................................................................................ 7.50 1000 ml OP ✔ Glucerna Select RTH ORAL FEED 1KCAL / ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid (vanilla)........................................................................... 1.88 250 ml OP ✔ Glucerna Select

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 May 2008

31 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g x 12.7 mm ...................................................................... 11.75 ❋ 31 g x 6 mm ........................................................................... 11.75 ❋ 31 g x 8 mm ........................................................................... 11.75 100 100 100 ✔ ABM ✔ ABM ✔ ABM

INSULIN SYRINGES DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g × 12.7 mm needle ........................... 14.45 100 ✔ ABM ❋ Syringe 0.3 ml with 31 g × 8 mm needle ................................ 14.45 100 ✔ ABM ❋ Syringe 0.5 ml with 29 g × 12.7 mm needle ........................... 14.45 100 ✔ ABM ❋ Syringe 0.5 ml with 31 g × 8 mm needle ................................ 14.45 100 ✔ ABM ❋ Syringe 1 ml with 29 g × 12.7 mm needle .............................. 14.45 100 ✔ ABM ❋ Syringe 1 ml with 31 g × 8 mm needle ................................... 14.45 100 ✔ ABM CONDOMS ❋ 53 mm (chocolate) .................................................................... 1.11 ❋ 53 mm (strawberry) .................................................................. 1.11 VALACICLOVIR Tab 500 mg .......................................................................... 163.80 12 12 30 ✔ Gold Knight ✔ Gold Knight

91 95 108

✔ Valtrex ✔ Norvir ✔ Efexor XR

RITONAVIR – Special Authority see SA0779 on page 93 – Hospital pharmacy [HP1] Cap 100 mg .......................................................................... 121.27 84 VENLAFAXINE – Special Authority see SA0789 below – Retail pharmacy Cap 37.5 mg ........................................................................... 18.64 28

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 June 2008

54 LOSARTAN ➽ SA0862 Special Authority for Subsidy Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 2.3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years. ➽ SA0911 Special Authority for Subsidy Initial application – (ACE inhibitor intolerant) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has persistent ACE inhibitor induced cough that has recurred by ACE inhibitor retrial (same or new ACE inhibitor); or 2 Patient has a history of angioedema. Initial application - (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient’s condition is not adequately controlled on maximum tolerated dose of an ACE inhibitor. Initial application (patient has had an approval for losartan with hydrochlorothiazide prior to 1 May 2008) from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. 54 LOSARTAN WITH HYDROCHLOROTHIAZIDE ➽ SA0862 Special Authority for Subsidy Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Both: 1.1 Patient with congestive heart failure; and 1.2 Either: 1.2.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or 1.2.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or 2 All of the following: 2.1 Patient with raised blood pressure; and 2.2 Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and 2.3 Either: continued... 2.3.1 Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... 2.3.2 Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years.

➽ SA0911 Special Authority for Subsidy Initial application – (ACE inhibitor intolerant) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has persistent ACE inhibitor induced cough that has recurred by ACE inhibitor retrial (same or new ACE inhibitor); or 2 Patient has a history of angioedema. Initial application - (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient’s condition is not adequately controlled on maximum tolerated dose of an ACE inhibitor. Initial application (patient has had an approval for losartan with hydrochlorothiazide prior to 1 May 2008) from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. 109 GABAPENTIN ➽ SA0873 Special Authority for Subsidy Initial application — (Epilepsy - new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Either: 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin, topiramate, vigabatrin and/or lamotrigine. Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Initial application — (Neuropathic pain - new patients) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant AND an anticonvulsant agent. Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August 2007) from any relevant practitioner. Approvals valid for 2 years where the patient has demonstrated a marked improvement in their control of pain (prescriber determined). Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years where the patient has demonstrated a marked improvement in their control of pain (prescriber determined). Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

110 TOPIRAMATE ➽ SA0874 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Patient has epilepsy; and 2 Either: 2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life life from gabapentin, topiramate, vigabatrin and/or lamotrigine.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 111 VIGABATRIN ➽ SA0875 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: All of the following: 1 Patient has epilepsy; and 2 Either: 2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and 3 Either: 3.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or 3.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin, topiramate, vigabatrin and/or lamotrigine; and continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life; and 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 164 CARBOHYDRATE ➽ SA0579 SA0912 Special Authority for Subsidy Initial application - (Cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Either: 1 cystic fibrosis; or 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient. Initial application - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: Any of the following: 1 cancer in children; or 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or 3 failure to thrive; or 4 growth deficiency; or 5 bronchopulmonary dysplasia; or 6 premature and post premature infant; or 7 inborn errors of metabolism Renewal - (Cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted. Renewal - (Indications other than cystic fibrosis or renal failure) only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: continued...

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 June 2008 (continued)

continued... Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 General Practitioners must include the name of the specialist and date contacted.

Effective 1 May 2008

91 PYRAZINAMIDE – Retail pharmacy-Specialist No patient co-payment payable ❋ Tab 500 mg ........................................................................... 59.00 100 ✔ AFT-Pyrazinamide

S29

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 June 2008

54 LOSARTAN – Special Authority see SA0911 ( subsidy) ❋ Tab 12.5 mg ........................................................................... 17.40 ❋ Tab 50 mg ............................................................................. 23.10 30 30 ✔ Cozaar ✔ Cozaar

54 66 86

LOSARTAN WITH HYDROCHLOROTHIAZIDE – Special Authority see SA0911 ( subsidy) Tab 50 mg with hydrochlorothiazide 12.5 mg........................... 30.00 30 ✔ Hyzaar PARAFFIN ( subsidy) White soft – Only in combination ............................................. 20.20 CEFUROXIME SODIUM – Hospital Pharmacy [HP3] ( subsidy) Inj 750 mg - Maximum of 1 inj per prescription; can be waived by endorsement ............................................ 10.71 Inj 1.5 g - Hospital pharmacy [HP3] – Specialist – Subsidy by endorsement ....................................................... 4.04 ASPIRIN ( subsidy) ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ....... 21.50 (22.50) MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 4.50 Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 4.98 2,500 g

✔ IPW

5 1 1000

✔ Zinacef ✔ Zinacef

103

Ethics Aspirin

105

5 5

✔ Mayne ✔ Mayne

147

SALBUTAMOL ( subsidy) Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO........................................................ 3.80 200 dose OP ✔ Salamol (6.00) Ventolin ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BENZETHONIUM ( subsidy) Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02 % .............................................. 6.97 35 ml OP ✔ Vosol CARBOHYDRATE AND FAT SUPPLEMENT – Special Authority see SA0581 – Hospital pharmacy [HP3] ( subsidy) Powder (neutral) ..................................................................... 60.31 400 g OP

151

164

✔ Duocal Super Soluble Powder

166

FAT SUPPLEMENT – Special Authority see SA0899 – Hospital pharmacy [HP3] ( subsidy) Oil ........................................................................................... 28.73 250 ml OP ✔ Liquigen 30.00 500 ml OP ✔ MCT oil (Nutricia) FAT MODIFIED FEED – Special Authority see SA0615– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 60.48 400 g OP ✔ Monogen ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0607– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 78.97 400 g OP ✔ Generaid Plus

168 169

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 June 2008 (continued)

169 171 ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0606 – Hospital pharmacy [HP3] ( subsidy) Liquid ...................................................................................... 54.00 400 g OP ✔ Kindergen ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see SA0592 – Hospital pharmacy [HP3] ( subsidy) Liquid (grapefruit) ..................................................................... 9.50 250 ml OP ✔ Elemental 028 Extra Liquid (pineapple & orange) ...................................................... 9.50 250 ml OP ✔ Elemental 028 Extra Liquid (summer fruit) ................................................................ 9.50 250 ml OP ✔ Elemental 028 Extra MULTIVITAMINS – Special Authority see SA0600– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 36.00 100 g OP ✔ Paediatric Seravit LOW CALCIUM INFANT FORMULA – Special Authority see SA0601– Hospital pharmacy [HP3] ( subsidy) Powder ................................................................................... 44.40 400 g OP ✔ Locasol

179 180

Effective 1 May 2008

27 OMEPRAZOLE ( subsidy) ❋ Cap 10 mg ................................................................................ 2.00 ❋ Cap 20 mg ................................................................................ 2.85 ❋ Cap 40 mg ................................................................................ 3.35 46 60 DEXTROSE ( subsidy) ❋ Inj 50%, 10 ml – Up to 5 inj available on a PSO ........................ 22.75 GLYCERYL TRINITRATE ( subsidy) ❋ TDDS 5 mg ............................................................................. 16.56 ❋ TDDS 10 mg ........................................................................... 19.60 POVIDONE IODINE ( price) Skin preparation, povidone iodine 10% with 70% alcohol ............ 8.13 (18.63) 1.63 (6.04) SUNSCREENS, PROPRIETARY – Sunscreens by endorsement ( price) Crm........................................................................................... 1.74 (5.84) OESTRADIOL ( subsidy) ❋ Tab 2 mg .................................................................................. 4.12 (7.00) 28 28 28 ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Dr Reddy’s Omeprazole ✔ Biomed ✔ Nitroderm TTS ✔ Nitroderm TTS

5 30 30 500 ml

Orion 100 ml Orion 50 g OP Aquasun Oil Free Faces SPF 30+ 28 OP Estrofem ✔ AFT-Leflunomide ✔ AFT-Leflunomide

LEFLUNOMIDE – Special Authority see SA0635 – Retail Pharmacy ( subsidy) Tab 10 mg .............................................................................. 55.00 30 Tab 20 mg .............................................................................. 76.00 30

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 June 2008

12 “Close Control” means the dispensing of a Community Pharmaceutical, in accordance with a Prescription, in quantities less than one 90 Day Lot (or, in the case of for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of a), b) or c) apply. as applicable, where a) All of the following conditions are met: i) the Community Pharmaceutical is a tri-cyclic antidepressant, antipsychotic, benzodiazepine, a Class B Controlled Drug, or any other Community Pharmaceutical that has been prescribed for a patient who: 1A) is not a resident in a Penal Institution, Rest Home or Residential Disability Care Institution; and 2B) either of the following: i) in the opinion of the prescribing Practitioner Doctor, Midwife or Nurse Prescriber is: a. frail; or b. infirm; or c. unable to manage their medication without additional support; or d. intellectually impaired; or and e. requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient’s first changed Prescription only); and f. requires that Community Pharmaceutical to be dispensed in a smaller quantity than that for which it is currently funded, or ii) the Community Pharmaceutical is any of the following: a. a tri-cyclic antidepressant; or b. an antipsychotic; or c. a benzodiazepine; or d. a Class B Controlled Drug; and ii) the prescribing Practitioner Doctor, Midwife or Nurse Prescriber has: A) endorsed each Community Pharmaceutical on the Prescription clearly with the words “close control” or “CC”; and B) initialled the endorsement in their the prescribers own handwriting; and C)specified the maximum quantity or period of supply to be dispensed at any one time. b) All of the following conditions are met: i) The Community Pharmaceutical is prescribed for a patient who is a resident in a Rest Home or Residential Disability Care Institution; and A)the quantity or period of supply to be dispensed at any one time is not less than 28 days’ supply; and B)the prescriber or pharmacist has written the name of the Rest Home or Residential Disability Care Institution on the prescription; and C)the prescriber or pharmacist has: 1) written on the Prescription the words “close control” or “CC” (this applies to all medicines prescribed on the prescription), and 2) initialled the endorsement/annotation in their own handwriting; and 3) specified the maximum quantity or period of supply to be dispensed at any one time. c) All of the following conditions are met: i) where PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Community Pharmaceutical(s) “Close Control” without prescriber endorsement for a specified time; and ii) the dispensing pharmacist has: A)clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words “close control” or “CC”; and B)initialled the annotation in their own handwriting; and C)specified the maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to PSO

Effective 1 June 2008

CONDOMS 53 mm extra strength .....................144 55 mm ...........................................144 LEVONORGESTREL Tab 1.5 mg.....................................5

Effective 1 May 2008

CONDOMS 53 mm (chocolate) .........................144 55 mm (strawberry) .......................144

Changes to Sole Subsidised Supply

Effective 1 June 2008

For the list of new Sole Subsidised Supply products effective 1 June 2008 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 8-16.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 June 2008

27 62 PANTOPRAZOLE ❋ Tab 20 mg ............................................................................... 2.24 (22.00) ❋ Tab 40 mg ............................................................................... 3.36 (28.00) ECONAZOLE NITRATE Crm 1% ..................................................................................... 1.00 (1.30) 28 Somac 28 Somac 15 g OP Ecreme

87 87 131

CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA0657 Tab 250 mg ............................................................................. 7.75 14 ✔ Clarac ERYTHROMYCIN LACTOBIONATE Inj 1 g ....................................................................................... 6.50 MITOZANTRONE – PCT only – Specialist Inj 2 mg per ml, 10ml ........................................................... 330.00 1 1

✔ ERA

✔ Onkotrone

Effective 1 May 2008

47 WATER 1) On a prescription or Practitioner’s Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or 2) On a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops. Purified for inj 5 ml – Available on a PSO ................................... 9.31 50 ✔ AstraZeneca Purified for inj 10 ml – Available on a PSO ............................... 10.38 50 ✔ AstraZeneca RITONAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Oral liq 80 mg per ml ............................................................ 277.28 Note: The 90 ml OP of Norvir will continue to be listed fully subsidised. NAPROXEN SODIUM ❋ Tab 275 mg ............................................................................. 5.00 240 ml OP ✔ Norvir

100

✔ Synflex

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 May 2008 (continued)

119 ALPRAZOLAM – Retail pharmacy-Specialist Month Restriction Tab 250 µg .............................................................................. 4.77 (8.11) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 500 µg .............................................................................. 8.60 (16.26) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg ............................................................................... 15.70 (32.51) ‡ Safety cap for extemporaneously compounded oral liquid preparations. SULPHACETAMIDE SODIUM ❋ Eye drops 10% ......................................................................... 3.60 ACETYLCYSTEINE – Hospital pharmacy [HP1]-Specialist Inj 200 mg per ml, 10 ml ...................................................... 137.06 (242.50)

100 Xanax 100 Xanax 100 Xanax

152 161

15 ml OP 10

✔ Acetopt

Parvolex

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 July 2008

91 VALACICLOVIR Tab 500 mg .......................................................................... 163.80 30 ✔ Valtrex

Effective 1 August 2008

52 PRAZOSIN HYDROCHLORIDE ❋ Tab 1 mg .................................................................................. 2.99 ❋ Tab 2 mg ................................................................................. 4.00 ❋ Tab 5 mg ................................................................................. 6.50 100 100 100 ✔ Hyprosin ✔ Hyprosin ✔ Hyprosin

Effective 1 September 2008

103 ASPIRIN ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ....... 21.50 (22.50) 1000 Ethics Aspirin

Effective 1 November 2008

58 95 VERAPAMIL HYDROCHLORIDE ❋ Tab 80 mg ............................................................................... 6.00 100 ✔ Verpamil ✔ Norvir

RITONAVIR – Special Authority see SA0779 on page 93 – Hospital pharmacy [HP1] Cap 100 mg .......................................................................... 242.55 168 Note – the 84 pack size will continue to be listed fully subsidised

Effective 1 December 2008

30 73 TOLBUTAMIDE ❋ Tab 500 mg ............................................................................ 12.00 LEVONORGESTREL ❋ Tab 750 µg .............................................................................. 8.50 a) Maximum of 4 tab per prescription b Up to 10 tab available on a PSO CYPROTERONE ACETATE – Hospital pharmacy [HP3] – Specialist Inj 100 mg per ml, 3 ml ......................................................... 196.82 OESTRADIOL VALERATE ❋ Tab 1 mg .................................................................................. 4.12 ORPHENADRINE CITRATE Inj 30 mg per ml, 2 ml ............................................................... 9.60 (20.50) 100 2 ✔ Diatol ✔ Postinor-2

78 79 102

3 28 3

✔ Androcur Depot

✔ Progynova

Norflex

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 December 2008 (continued)

114 PROCHLORPERAZINE ❋ Suppos 5 mg............................................................................. 9.52 (18.13) 5 Stemetil

168 168

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid ........................................................................................ 7.50 1,000 ml OP ✔ Glucerna RTH ORAL FEED 1KCAL / ML Liquid (vanilla)........................................................................... 1.88 250 ml OP ✔ Glucerna Note : Glucerna RTH and Glucerna replaced by Glucerna Select RTH and Glucerna See New Listings

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes

Effective 1 June 2008

CEFUROXIME SODIUM ( price and addition of HSS) Inj 750 mg .....................................Zinacef 10.71 5 1% Aug-08 Axetine Pacific Mayne Zilisten Axetine Pacific Mayne Zilisten Mayne Mini-Jet

Inj 1.5 g..........................................Zinacef

4.04

Aug-08

DEXTROSE Inj 50%, 10 ml ................................Biomed HYDROXOCOBALAMIN Inj 1mg per ml, 1 ml .......................ABM LAMOTRIGINE Tab dispersible 25 mg ....................Logem Tab dispersible 50 mg ....................Logem Tab dispersible 100 mg ..................Logem MORPHINE SULPHATE ( price and addition of HSS) Inj 10 mg per ml, 1 ml ....................Mayne Inj 30 mg per ml, 1 ml ....................Mayne RIZATRIPTAN BENZOATE Wafer 10 mg .................................Maxalt Melt

22.75

July-08

9.21 19.38 32.97 56.91 4.50 4.98 25.32

3 56 56 56 5 5 3 1% 1% Aug-08 Aug-08 (B) (B)

Effective 1 May 2008

DEXTROSE ( price and addition of HSS) Inj 50%, 10 ml ................................Biomed GLYCERYL TRINITRATE ( price and addition of HSS) TDDS 5 mg ....................................Nitroderm TTS TDDS 10 mg ..................................Nitroderm TTS 22.75 5 1% July-08 Mayne Mini-Jet Minitran Nitrocor Nitro-Dur Minitran Nitrocor Nitro-Dur

16.56 19.60

1% 1%

July-08 July-08

INSULIN PEN NEEDLES 29 g x 12.7 mm..............................ABM 31 g x 6 mm...................................ABM 31 g x 8 mm...................................ABM

11.75 11.75 11.75

100 100 100

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes - effective 1 May 2008 (continued)

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE Syringe 0.3 ml with 29 g x 12.7 mm needle ..............ABM 14.45 Syringe 0.3 ml with 31 g x 8 mm needle ...................ABM 14.45 Syringe 0.5 ml with 29 g x 12.7 mm needle ..............ABM 14.45 Syringe 0.5 ml with 31 g x 8 mm needle ...................ABM 14.45 Syringe 1 ml with 29 g x 12.7 mm needle ..............ABM 14.45 Syringe 1 ml with 31 g x 8 mm needle ...................ABM 14.45 LEFLUNOMIDE ( price) Tab 10 mg......................................AFT-Leflunomide 55.00 Tab 20 mg......................................AFT-Leflunomide 76.00 OMEPRAZOLE ( price) Cap 10 mg ....................................Dr Reddy’s Omeprazole Cap 20 mg .....................................Dr Reddy’s Omeprazole Cap 40 mg .....................................Dr Reddy’s Omeprazole 2.00 2.85 3.35

100 100 100 100 100 100 30 30 28 28 28

RITONAVIR Cap 100 mg ...................................Norvir 121.27 Cap 100 mg ...................................Norvir 242.55 Note – 168 pack size of Norvir to be delisted from 1 May 2008 VENLAFAXINE Cap 37.5 mg ..................................Efexor XR VERAPAMIL Tab 80 mg .....................................Verpamil Verpamil tab 80 mg to be delisted from 1 May 2008 18.64 6.00

84 168

28 100

Section H Changes - effective 1 April 2008

There are no changes to Section H for 1 April 2008.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A ABM Hydroxocobalamin ..................................... 18 Acetic acid with 1, 2- propanediol diacetate and benzethonium ........................................... 25 Acetopt .............................................................. 30 Acetylcysteine.................................................... 30 AFT-Leflunomide .......................................... 26, 34 AFT-Pyrazinamide .............................................. 24 Alprazolam ......................................................... 30 Androcur Depot .................................................. 31 Aquasun Oil Free Faces SPF 30+ Confidence ..... 26 Aspirin ......................................................... 25, 31 C Carbohydrate ..................................................... 23 Carbohydrate and fat supplement ....................... 25 Cefuroxime sodium ...................................... 25, 33 Clarac ................................................................ 29 Clarithromycin.................................................... 29 Condoms ............................................... 18, 19, 28 Cozaar ......................................................... 18, 25 Cyproterone acetate ........................................... 31 D Dextrose ...................................................... 26, 33 Diabetic enteral feed 1kcal/ml ....................... 18, 32 Diatol ................................................................. 31 Dr Reddy’s Omeprazole................................ 26, 34 Duocal Super Soluble Powder ............................ 25 E Econazole nitrate ................................................ 29 Ecreme .............................................................. 29 Efexor XR ..................................................... 19, 34 Elemental 028 Extra ........................................... 26 Enteral/oral feed 1kcal/ml ............................. 25, 26 ERA ................................................................... 29 Erythromycin lactobionate .................................. 29 Estrofem ............................................................ 26 Ethics Aspirin ............................................... 25, 31 F Fat modified feed................................................ 25 Fat supplement .................................................. 25 Fortisip Powder .................................................. 18 G Gabapentin ........................................................ 21 Generaid Plus..................................................... 25 Glucerna ............................................................ 32 Glucerna RTH .................................................... 32 Glucerna Select .................................................. 18 Glucerna Select RTH .......................................... 18 Glyceryl trinitrate .......................................... 26, 33 Gold Knight .................................................. 18, 19 H Heparinised saline .............................................. 18 Hydroxocobalamin ....................................... 18, 33 Hyprosin ............................................................ 31 Hyzaar ............................................................... 25 I Insulin pen needles....................................... 19, 33 Insulin syringes disposable with attached needle 19 Insulin syringes, disposable with attached needle 34 K Kindergen .......................................................... 26 L Lamotrigine.................................................. 18, 33 Leflunomide ................................................. 26, 34 Levonorgestrel ....................................... 18, 28, 31 Liquigen ............................................................. 25 Locasol.............................................................. 26 Logem ......................................................... 18, 33 Losartan ................................................ 18, 20, 25 Losartan with hydrochlorothiazide ................ 20, 25 Low calcium infant formula ................................ 26 M Maxalt Melt .................................................. 18, 33 MCT oil (Nutricia) ............................................... 25 Mitozantrone ...................................................... 29 Monogen ........................................................... 25 Morphine sulphate........................................ 25, 33 Multivitamins ..................................................... 26 N Naproxen sodium ............................................... 29 Nitroderm TTS.............................................. 26, 33 Norflex ............................................................... 31 Norvir .............................................. 19, 29, 31, 34 O Oestradiol .......................................................... 26 Oestradiol valerate........................................ 18, 31 Omeprazole.................................................. 26, 34 Onkotrone .......................................................... 29 Oral elemental feed 0.8kcal/ml............................ 26 Oral feed 1kcal / ml ...................................... 18, 32 Oral supplement 1kcal/ml ................................... 18 Orphenadrine citrate ........................................... 31 P Paediatric Seravit ............................................... 26 Pantoprazole ...................................................... 29 Paraffin .............................................................. 25 Parvolex ............................................................. 30 Postinor-1.......................................................... 18 Postinor-2.......................................................... 31 Povidone iodine ................................................. 26 Prazosin hydrochloride ....................................... 31 Prochlorperazine ................................................ 32 Progynova ................................................... 18, 31 Pyrazinamide ..................................................... 24

Index

Pharmaceuticals and brands R Respigen ........................................................... 18 Ritonavir .......................................... 19, 29, 31, 34 Rizatriptan benzoate ..................................... 18, 33 S Salamol ............................................................. 25 Salbutamol................................................... 18, 25 Somac ............................................................... 29 Stemetil ............................................................. 32 Sulphacetamide sodium ..................................... 30 Sunscreens, proprietary ..................................... 26 Synflex............................................................... 29 T Tolbutamide ....................................................... 31 Topiramate......................................................... 22 V Valaciclovir .................................................. 19, 31 Valtrex ......................................................... 19, 31 Venlafaxine .................................................. 19, 34 Ventolin ............................................................. 25 Verapamil .......................................................... 34 Verapamil hydrochloride ..................................... 31 Verpamil ...................................................... 31, 34 Vigabatrin .......................................................... 22 Vosol ................................................................. 25 W Water ................................................................. 29 X Xanax................................................................. 30 Z Zinacef ......................................................... 25, 33

Pharmaceutical Management Agency Level 14, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 June 2008

Abstract

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.